When will the LungVax clinical trial begin?

The first phase of the LungVax clinical trial is expected to commence in summer 2026.

How does the LungVax vaccine work?

LungVax uses mRNA technology to train the immune system to recognize and destroy abnormal lung cells before they become cancerous.

Who is eligible for the LungVax trial?

The trial will include patients at high risk of lung cancer, including those previously treated for early-stage lung cancer and participants in the NHS Lung Cancer Screening Programme.

Home / Health / World's First Lung Cancer Vaccine Trial Begins

World's First Lung Cancer Vaccine Trial Begins

24 Nov

•

Summary

The first-ever vaccine designed to prevent lung cancer is entering a clinical trial.
The LungVax trial will investigate the best dose and potential side effects.
The vaccine uses mRNA technology to train the immune system against cancer cells.

World's First Lung Cancer Vaccine Trial Begins

A pioneering clinical trial for the world's first lung cancer preventative vaccine, LungVax, is scheduled to begin in summer 2026. Funded by Cancer Research UK, this four-year study will assess the vaccine's safety and optimal dosage in individuals at high risk of the disease. The vaccine utilizes mRNA technology, similar to COVID-19 vaccines, to train the immune system to recognize and eliminate abnormal lung cells by targeting specific proteins.

The trial will initially enroll patients who have successfully undergone treatment for early-stage lung cancer and are thus at high risk of recurrence, as well as those participating in the NHS Lung Cancer Screening Programme. Experts emphasize that while preventative vaccines offer a promising new avenue, they will not replace smoking cessation as the primary method for reducing lung cancer risk.